类风湿性关节炎与带状疱疹：接受抗肿瘤坏死因子治疗患者的风险及预防 - Suppr

Suppr

超能文献

Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy.

作者信息

Winthrop K L, Furst D E

出版信息

Ann Rheum Dis. 2010 Oct;69(10):1735-7. doi: 10.1136/ard.2010.133843.

DOI:10.1136/ard.2010.133843

PMID:20858622

Abstract

摘要

相似文献

Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy.类风湿性关节炎与带状疱疹：接受抗肿瘤坏死因子治疗患者的风险及预防

Ann Rheum Dis. 2010 Oct;69(10):1735-7. doi: 10.1136/ard.2010.133843.

Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?治疗：带状疱疹的风险：抗TNF治疗的又一项代价？

Nat Rev Rheumatol. 2009 Jul;5(7):361-3. doi: 10.1038/nrrheum.2009.120.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.接受抗TNF-α药物治疗的类风湿关节炎患者发生带状疱疹的风险。

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.抗肿瘤坏死因子治疗的起始与带状疱疹风险之间的关联。

JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099.

Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.一名接受阿达木单抗治疗类风湿关节炎的患者发生了假性淋巴瘤样皮肤利什曼病。

Acta Derm Venereol. 2009;89(4):432-3. doi: 10.2340/00015555-0633.

No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.使用日本健康保险数据库的流行病学研究：类风湿关节炎患者使用肿瘤坏死因子抑制剂和非肿瘤坏死因子抑制剂并无增加带状疱疹风险

Int J Rheum Dis. 2018 Sep;21(9):1670-1677. doi: 10.1111/1756-185X.13300. Epub 2018 Apr 17.

Herpes zoster in the age of focused immunosuppressive therapy.聚焦免疫抑制治疗时代的带状疱疹

JAMA. 2009 Feb 18;301(7):774-5. doi: 10.1001/jama.2009.150.

Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.根据生物改善病情疗法，类风湿关节炎患者发生带状疱疹的风险

Arthritis Care Res (Hoboken). 2015 May;67(5):731-6. doi: 10.1002/acr.22470.

Pneumococcal vaccination for RA patients on TNF-alpha antagonists.类风湿关节炎患者使用肿瘤坏死因子-α拮抗剂时的肺炎球菌疫苗接种

Rheumatology (Oxford). 2004 Apr;43(4):523. doi: 10.1093/rheumatology/keh167.

Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.类风湿关节炎患者带状疱疹的危险因素：肿瘤坏死因子-α抑制剂的作用。

Intern Med J. 2015 Mar;45(3):310-8. doi: 10.1111/imj.12679.

引用本文的文献

Increased Risk of Herpes Zoster in Rheumatoid Arthritis Not Only Due to JAK Inhibitors-Study of 392 Patients from Single University Center.类风湿关节炎患者带状疱疹风险增加不仅归因于JAK抑制剂——来自单一大学中心的392例患者研究

J Clin Med. 2024 May 26;13(11):3121. doi: 10.3390/jcm13113121.

CD4/CD8 Ratio: An Independent Predictor of Herpes Zoster in Patients With Autoimmune Inflammatory Rheumatic Diseases.CD4/CD8 比值：自身免疫性炎性风湿性疾病患者带状疱疹的独立预测指标

Ann Dermatol. 2024 Jun;36(3):163-171. doi: 10.5021/ad.23.126.

Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.托法替布治疗印度类风湿关节炎患者的疗效和安全性：3 期研究及 7 年长期扩展研究的事后分析。

Int J Rheum Dis. 2020 Jul;23(7):882-897. doi: 10.1111/1756-185X.13853. Epub 2020 Jun 1.

Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs.类风湿关节炎患者接受生物性改善病情抗风湿药治疗后带状疱疹的自然病程及特异性免疫研究。

Mediterr J Rheumatol. 2017 Sep 29;28(3):164-168. doi: 10.31138/mjr.28.3.164. eCollection 2017 Sep.

Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib.类风湿关节炎患者后续接受托法替布治疗时，活带状疱疹疫苗的长期有效性。

Ann Rheum Dis. 2020 May;79(5):669-671. doi: 10.1136/annrheumdis-2019-216566. Epub 2020 Mar 11.

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.在类风湿关节炎、中轴型脊柱关节炎、银屑病关节炎、银屑病和克罗恩病患者中的长期安全性：来自临床试验的 11317 例患者的汇总分析。

RMD Open. 2019 May 31;5(1):e000942. doi: 10.1136/rmdopen-2019-000942. eCollection 2019.

In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.真实世界：生物制剂和小分子药物治疗银屑病关节炎和银屑病相关感染。

Curr Rheumatol Rep. 2019 Jun 6;21(7):36. doi: 10.1007/s11926-019-0832-y.

Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study.银屑病患者带状疱疹风险增加：一项基于人群的回顾性队列研究。

PLoS One. 2017 Aug 22;12(8):e0179447. doi: 10.1371/journal.pone.0179447. eCollection 2017.

The emerging safety profile of JAK inhibitors in rheumatic disease.新型 JAK 抑制剂在风湿性疾病中的安全性概况。

Nat Rev Rheumatol. 2017 Apr;13(4):234-243. doi: 10.1038/nrrheum.2017.23. Epub 2017 Mar 2.

Adverse reactions to biologic agents and their medical management.生物制剂的不良反应及其医学管理。

Nat Rev Rheumatol. 2014 Oct;10(10):612-27. doi: 10.1038/nrrheum.2014.123. Epub 2014 Aug 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验